Loading clinical trials...
Loading clinical trials...
Post-marketing Surveillance of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix When Administered According to the Approved Prescribing Information in Korea
Conditions
Interventions
Safety data collection (following routine vaccination) by a continuous surveillance method.
Locations
29
South Korea
GSK Investigational Site
Busan, South Korea
GSK Investigational Site
Chungcheongnam-do, South Korea
GSK Investigational Site
Daegu, South Korea
GSK Investigational Site
Gongju-si, Chungcheongnam-do, South Korea
GSK Investigational Site
Gwangju, South Korea
GSK Investigational Site
Gyeonggi-do, South Korea
Start Date
October 2, 2018
Primary Completion Date
December 1, 2020
Completion Date
December 1, 2020
Last Updated
February 23, 2023
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions